Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

References

• Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Aβ-42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5–8
   PubMed Web of Science ®Google Scholar
• Andreasen N, Vanmechelen E, Vanderstichele H, et al. Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 2003; 107(Suppl 179)47–51
   Google Scholar
• Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856–861
   PubMed Web of Science ®Google Scholar
• Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older person. Neurology 2002; 59: 198–205
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605–613
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993; 88: 221–223
   PubMed Web of Science ®Google Scholar
• Blomberg M, Jensen M, Basun H, Lanfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer's disease patients with apolipoprotein E allele ε4 during 14 months follow-up. Neurosci Lett 1996; 214: 163–166
   PubMed Web of Science ®Google Scholar
• Bouwman FH, Schoonenboom SNM, van der Flier WM, et al 2006. CSF biomarkers and medial temporal lobe atrophy predicit dementia in mild cognitive impairment. Neurobiol Aging DOI: 10.1016/j.neurobiolaging.2006.5.006.
   PubMedGoogle Scholar
• Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment. Risk of Alzheimer disease and rate of cognitive decline. Neurology 2006; 67: 441–445
   PubMed Web of Science ®Google Scholar
• Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004; 16: 128–140
   Google Scholar
• Buerger K, Teipel SJ, Zinkowski R, et al. Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. Neurosci Lett 2005; 391: 48–50
   PubMed Web of Science ®Google Scholar
• Citron M. β-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res 2002; 70: 373–9
   PubMed Web of Science ®Google Scholar
• Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and β-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnosis?. Arch Neurol 2003; 60: 1696–1702
   PubMed Web of Science ®Google Scholar
• DeCarli C. Mild Cognitive Impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 15–21
   PubMed Web of Science ®Google Scholar
• Fagan AM, Roe CM, Xiong C, Mintun MA., Morris JC, Holtzman D. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343–349
   PubMed Web of Science ®Google Scholar
• Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: An epidemiological study. Neurology 2004; 63: 115–121
   PubMed Web of Science ®Google Scholar
• Goedert M. Tau protein and neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993; 16: 460–465
   PubMed Web of Science ®Google Scholar
• Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF β-amyloid1–42and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9: 705–710
   PubMed Web of Science ®Google Scholar
• Hansson O, Zetterberg H, Buchlave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228–234
   PubMed Web of Science ®Google Scholar
• Hedges L, Olkin I. Statistical methods for meta-analysis. Academic Press, London 1985
   Google Scholar
• Herukka SK, Hallinkainen M, Soininen H, Pirttilä T. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64: 1294–1297
   PubMed Web of Science ®Google Scholar
• Herukka SK, Helisalmi S, Hallinkainen, Tervo S, Soininen H, Pirttilä T. CSF Aβ42, Tau and phosphorylated Tau, APOE ε4 allele, and MCI type in progressive MCI. Neurobiol Aging 2007; 28: 507–514
   PubMed Web of Science ®Google Scholar
• Ivanoiu A, Sindic CJM. Cerebrospinal fluid TAU protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005; 11: 32–39
   PubMed Web of Science ®Google Scholar
• Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to dementia. Arch Neurol 2006; 63: 674–681
   PubMed Web of Science ®Google Scholar
• Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC: Cache County Study Investigators. 2004. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 61:518–524.
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 303–305
   PubMedGoogle Scholar
• Lewczuk P, Beck G, Ganslandt O, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 2006; 409: 1–4
   PubMedGoogle Scholar
• Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al 2007. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging DOI: 10.1016/j.neurobiolaging.2006.12.010.
   PubMedGoogle Scholar
• Maruyama M, Arai M, Sugita M, et al. Cerebrospinal fluid Amyloid β1–42 levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001; 172: 433–436
   PubMed Web of Science ®Google Scholar
• Maruyama M, Matsui T, Tanji H, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implication for 2 major pathways. Arch Neurol 2004; 61: 716–720
   PubMedGoogle Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–44
   PubMed Web of Science ®Google Scholar
• Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–2414
   PubMed Web of Science ®Google Scholar
• Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in ‘normal’ aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996; 46: 707–719
   PubMed Web of Science ®Google Scholar
• Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. J Am Med Assoc 2000; 283: 1571–2577
   PubMed Web of Science ®Google Scholar
• Okamura N, Arai H, Maruyama M, et al. Combined analysis of CSF tau levels and [123I] Iodoamphetamine SPECT in mild cognitive impairment: implication for a novel predictor of Alzheimer's disease. Am J Psychiatry 2002; 159: 474–476
   PubMed Web of Science ®Google Scholar
• Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of β-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP techonology. Clin Chem 2005; 51: 336–345
   PubMed Web of Science ®Google Scholar
• Parnetti L, Lanari A, Sivestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech Aging Dev 2006; 127: 129–132
   PubMedGoogle Scholar
• Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid β-amyloid 42 in adults with normal cognition. Arch Neurol 2006; 63: 936–939
   PubMedGoogle Scholar
• Petersen RC, Doody R, Kurz A, et al. Mild Cognitive Impairment: Clinical Characterization and Outcome. Arch Neurol 1999; 56: 303–308
   PubMed Web of Science ®Google Scholar
• Petersen RC, Parisi JE, Dickson DW, et al. Neuropathological features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665–672
   PubMed Web of Science ®Google Scholar
• Price JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology 2004; 63: 2116–2118
   Google Scholar
• Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer's disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59: 1729–1734
   PubMed Web of Science ®Google Scholar
• Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001; 56: 37–42
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–177
   PubMed Web of Science ®Google Scholar
• Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652–656
   PubMed Web of Science ®Google Scholar
• Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1200–1205
   PubMed Web of Science ®Google Scholar
• The Ronald and Nancy Reagan Research Institute of the Alzheimer's Disease Association and The National Institute on Aging Working Group. 1998. Consensus Report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer's Disease’. Neurobiol Aging 19:109–116.
   PubMed Web of Science ®Google Scholar
• Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: The Cache County Study. Neurology 2006; 67: 229–234
   PubMed Web of Science ®Google Scholar
• Valenzuela MJ, Sachdev P. Brain reserve and dementia: systematic review. Psychol Med 2006; 36: 441–454
   PubMed Web of Science ®Google Scholar
• Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; 67: 1201–7
   PubMed Web of Science ®Google Scholar
• Winblad B, Palmer K, Kivipelto M, et al. Mild Cognitive Impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Int Medicine 2004; 256: 240–246
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003; 352: 67–69
   PubMed Web of Science ®Google Scholar